Eden Research plc - Patents granted in the United States
("Eden" or "Company")
Patents granted in
Patents for Eden's Sustaine® encapsulation technology and compositions for insecticide products have both been granted by the US Patent Office. Sustaine microcapsules are naturally sourced, plastic-free, biodegradable micro-spheres derived from yeast extract. Importantly, the Sustaine microencapsulation technology enables the use of naturally occurring terpenes for application in commercial crop protection.
The initial patent provides broad compositional protection for the encapsulation of terpenes in hollow cell wall particles. The second patent provides protection for the use of compositions in a method of killing mites or treating/preventing a mite infestation, which is a designed use for Eden's new insecticide products.
Eden outlined its intention to use a proportion of the proceeds from its fundraising in
The insecticide products will be additions to the Company's current suite of products. Eden's biopesticide product portfolio is based upon the powerful combination of plant-derived active ingredients and the Sustaine microencapsulation system. Eden's plant protection products offer ease of use and efficacy on par with conventional pesticides whilst being exempt from maximum residue levels in
For further information contact:
| || |
01285 359 555
Cenkos Securities plc (Nominated advisor and broker)
| || |
020 7397 8900
| || |
Eden's Sustaine encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can be used with both natural and synthetic compounds to enhance their performance and ease-of-use.
Sustaine microcapsules are naturally derived, plastic-free, biodegradable micro-spheres derived from yeast extract. They produce stabilised aqueous suspensions which, are easy to mix and apply, have phased release patterns, are safer for the environment and the crops themselves.
By 2025 in the EU, pesticides containing synthetic polymer microplastics are likely to be banned and removed from the market. The only acceptable alternative is the substitution with biodegradable formulations. Reformulated products will need to be evaluated and registered within the five-year transition period.
Sustaine is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Sustaine provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of 14m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.
Mevalone is a foliar fungicide which has been authorised for sale in
Cedroz is a nematicide which has been authorised for sale in
Eden was admitted to trading on AIM on
This information is provided by RNS, the news service of the
Quick facts: Eden Research PLC
Market Cap: £32.9 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE